Please assess the completion status of the following clinical trial:

Trial Title: Ginger in Treating Nausea in Patients Receiving Chemotherapy for Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of cancer and be scheduled to receive at least 3 courses of chemotherapy~  * Scheduled to receive chemotherapy with no planned interruption by radiotherapy or surgery~ * Chemotherapy courses must be separated by at least 2 weeks from day 1 to day 1 of next course~* Must have experienced nausea of any degree of severity after completion of the first study-related course of chemotherapy~* Received a prior 5-hydroxytryptamine type 3 (5-HT3) receptor antagonist antiemetic (ondansetron, granisetron, tropisetron, or dolasetron mesylate) with dexamethasone (DM) given at any dose and by any route (or equivalent dose of IV methylprednisolone (MePRDL)) on day 1 of course 1 of chemotherapy~* Scheduled to receive a 5-HT3 receptor antagonist antiemetic with DM (or equivalent dose of IV MePRDL) on day 1 of courses 2 and 3 of chemotherapy~* No symptomatic brain metastases~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* Not specified~Life expectancy:~* Not specified~Hematopoietic:~* Platelet count greater than 100,000/mm\^3 at second course of chemotherapy~* No prior bleeding or blood coagulation disorder (e.g., thrombocytopenia or platelet dysfunction)~Hepatic:~* No prior coagulation factor deficiency~Renal:~* Not specified~Cardiovascular:~* No prior vascular defect~Other:~* Able to understand English~* No concurrent or impending bowel obstruction~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* No concurrent interferon therapy~Chemotherapy:~* See Disease Characteristics~* At least 6 months since other prior chemotherapy~Endocrine therapy:~* Not specified~Radiotherapy:~* See Disease Characteristics~* No concurrent radiotherapy~Surgery:~* See Disease Characteristics~Other:~* No concurrent warfarin or heparin for therapeutic anticoagulation~* Concurrent low-dose warfarin for maintenance of venous access allowed~* Concurrent rescue medications for control of symptoms caused by the cancer or its treatment allowed as clinically indicated

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Patients receive oral placebo twice daily on days -3 to 3 of chemotherapy courses 2 and 3.
- 0.5g ginger (Type: EXPERIMENTAL): Patients receive oral low-dose ginger and oral placebo twice daily on days -3 to 3 of chemotherapy courses 2 and 3.
- 1.0g ginger (Type: EXPERIMENTAL): Patients receive oral intermediate-dose ginger and oral placebo twice daily on days -3 to 3 of chemotherapy courses 2 and 3.
- 1.5g ginger (Type: EXPERIMENTAL): Patients receive oral high-dose ginger twice daily on days -3 to 3 of chemotherapy courses 2 and 3.

Based on this trial design, predict the completion outcome and termination type (if applicable).